Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Status:
Recruiting
Trial end date:
2024-02-29
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver
histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)